A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001

Bryan Oronsky, Scott Caroen, Karen Zeman, Mary Quinn, Christina Brzezniak, Jan Scicinski, Pedro Cabrales, Tony R. Reid, Jane B. Trepel, Nacer D. Abrouk, Christopher Larson, Arnold Oronsky, Harry E. Lybeck, Regina M. Day, Corey A. Carter

Research output: Contribution to journalArticle

Abstract

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalClinical Medicine Insights: Oncology
Volume10
DOIs
StatePublished - Nov 6 2016
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Platinum
Drug Therapy
Therapeutics
Topoisomerase I Inhibitors
Topotecan
Recurrence
Phase II Clinical Trials
Etoposide
United States Food and Drug Administration
RRx-001
Cisplatin
Lung Neoplasms
Neoplasms
Quality of Life
Clinical Trials
Survival

Keywords

  • Epigenetic
  • Platinum doublets
  • Resensitization
  • Resistance reversal
  • Resistant SCLC
  • RRx-001

ASJC Scopus subject areas

  • Oncology

Cite this

A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001. / Oronsky, Bryan; Caroen, Scott; Zeman, Karen; Quinn, Mary; Brzezniak, Christina; Scicinski, Jan; Cabrales, Pedro; Reid, Tony R.; Trepel, Jane B.; Abrouk, Nacer D.; Larson, Christopher; Oronsky, Arnold; Lybeck, Harry E.; Day, Regina M.; Carter, Corey A.

In: Clinical Medicine Insights: Oncology, Vol. 10, 06.11.2016, p. 105-108.

Research output: Contribution to journalArticle

Oronsky, B, Caroen, S, Zeman, K, Quinn, M, Brzezniak, C, Scicinski, J, Cabrales, P, Reid, TR, Trepel, JB, Abrouk, ND, Larson, C, Oronsky, A, Lybeck, HE, Day, RM & Carter, CA 2016, 'A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001', Clinical Medicine Insights: Oncology, vol. 10, pp. 105-108. https://doi.org/10.4137/CMO.S40429
Oronsky, Bryan ; Caroen, Scott ; Zeman, Karen ; Quinn, Mary ; Brzezniak, Christina ; Scicinski, Jan ; Cabrales, Pedro ; Reid, Tony R. ; Trepel, Jane B. ; Abrouk, Nacer D. ; Larson, Christopher ; Oronsky, Arnold ; Lybeck, Harry E. ; Day, Regina M. ; Carter, Corey A. / A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001. In: Clinical Medicine Insights: Oncology. 2016 ; Vol. 10. pp. 105-108.
@article{b8e41406cacc4765bfde0c69b35f7c70,
title = "A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001",
abstract = "As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10{\%} and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.",
keywords = "Epigenetic, Platinum doublets, Resensitization, Resistance reversal, Resistant SCLC, RRx-001",
author = "Bryan Oronsky and Scott Caroen and Karen Zeman and Mary Quinn and Christina Brzezniak and Jan Scicinski and Pedro Cabrales and Reid, {Tony R.} and Trepel, {Jane B.} and Abrouk, {Nacer D.} and Christopher Larson and Arnold Oronsky and Lybeck, {Harry E.} and Day, {Regina M.} and Carter, {Corey A.}",
year = "2016",
month = "11",
day = "6",
doi = "10.4137/CMO.S40429",
language = "English (US)",
volume = "10",
pages = "105--108",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001

AU - Oronsky, Bryan

AU - Caroen, Scott

AU - Zeman, Karen

AU - Quinn, Mary

AU - Brzezniak, Christina

AU - Scicinski, Jan

AU - Cabrales, Pedro

AU - Reid, Tony R.

AU - Trepel, Jane B.

AU - Abrouk, Nacer D.

AU - Larson, Christopher

AU - Oronsky, Arnold

AU - Lybeck, Harry E.

AU - Day, Regina M.

AU - Carter, Corey A.

PY - 2016/11/6

Y1 - 2016/11/6

N2 - As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.

AB - As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.

KW - Epigenetic

KW - Platinum doublets

KW - Resensitization

KW - Resistance reversal

KW - Resistant SCLC

KW - RRx-001

UR - http://www.scopus.com/inward/record.url?scp=85009471471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009471471&partnerID=8YFLogxK

U2 - 10.4137/CMO.S40429

DO - 10.4137/CMO.S40429

M3 - Article

C2 - 27840583

AN - SCOPUS:85009471471

VL - 10

SP - 105

EP - 108

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -